Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

bone giant cell tumor - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

bone giant cell tumor

MONDO:0005674

Also known as:GCT of boneOsteoclastoma, benignbenign bone giant cell tumor

Find Clinical TrialsTrials

Overview

A benign but locally aggressive tumor that arises from the bone and is composed of mononuclear cells admixed with macrophages and osteoclast-like giant cells. It usually arises from the ends of long bones or the vertebrae. Clinical presentation includes pain, edema, and decreased range of motion in the affected joint.

Treatments2 FDA approved, newest 2025

Clinical Trials9 registered · 5 recruiting

Diagnosis

Biomarker and diagnostic research for bone giant cell tumor has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

2 FDA-approved treatments are available for bone giant cell tumor, including DENOSUMAB (BILPREVDA, approved 2025) and DENOSUMAB-MOBZ (OZILTUS, approved 2025).

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

9 clinical trials registered, 5 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 2 PHASE4, 2 PHASE3, 2 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT05595603](https://clinicaltrials.gov/study/NCT05595603)

Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 12:04 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:363976

GARD

Genetic and Rare Diseases Info Center

GARD:13046

Questions for Your Care Team

→What are the benefits and potential side effects of BILPREVDA for managing bone giant cell tumor?
→Are any of the 9 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Patient case studies	41	37%
Research summaries	36	33%
Clinical study results	11	10%
Disease patterns and progression	10	9%
Testing and diagnosis research	4	4%
Laboratory research	4	4%
Other research	3	3%
New treatment approaches	1	1%

bone giant cell tumor

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications